Page 1 of 1

IONS −17–19%: Ionis halves Tryngolza 2026 guidance to ~$50m despite Q3 revenue +55%

Posted: Mon Nov 09, 2026 3:21 pm
by LondonNewsTrader
Ionis Pharmaceuticals gapped down hard this morning, about 17–19% premarket and heading toward 19-month lows, after Q3 results before the bell.

What happened:
- Total Q3 revenue rose about 55% year on year to $243m, and the net loss narrowed.
- The problem is Tryngolza (olezarsen, the severe hypertriglyceridemia launch): Q3 US net sales were $9m against a consensus of around $21m, according to Reuters via Boursorama.
- 2026 Tryngolza guidance was cut to about $50m from $100–110m, roughly half at the midpoint. Management blames a slower launch ramp while doctors adopt a new treatment approach.
- Total revenue guidance of $875–900m, the operating loss outlook and cash guidance were all reaffirmed, and Dawnzera guidance was kept.

So this is a launch-credibility gap, not a balance-sheet scare. The stock was already down about 50% this year coming in, which makes it tempting to call a bottom. With Tryngolza being the main commercial story, I'd expect sellers to defend any morning pop before buyers get much room.

Sources: [Ionis Q3 release](https://ir.ionis.com/news-releases/news ... esults-and), [Investing.com on the drop](https://www.investing.com/news/stock-ma ... CH-5011647). Not advice.

Do you short guidance-cut gaps in biotech or leave them alone because of headline risk? Where would you want to see IONS hold before trying a long?